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It is of interest to study the cytotoxicity of silibinin assisted silver nanoparticles in human colorectal (HT-29) cancer cells. Silver 
nanoparticles were synthesized using silibinin as a reducing agent. The synthesized silibinin assisted silver nanoparticles (SSNPs) were 
characterized and analyzed using a transmission electron microscope and spectrophotometer. The SSNPs synthesized in this study are 
spherical and their size ranges from 10 to 80 nm. HT-29 cells were treated with different concentrations (2, 4, 6, 8 and 10 ng/mL) of SSNPs 
and cytotoxicity was evaluated. The apoptosis was using flow cytometry. p53 protein expression using western blot. SSNPs are induced a 
decrease in viability and increased concentration-dependent cytotoxicity in HT-29 cells. SSNPs treatment also caused apoptosis-related 
morphological changes. SSNPs treatments at 8 and 16 ng/ml showed a prominent apoptotic change i.e., 70.3% and 83.6% respectively, and 
decreased viability of HT-29 cells 20% and 11.2% respectively as compared to control cells. SSNPs treatments induced p53 expression in 
HT-29 cells. Data shows that SSNPs have the potential to induce apoptosis in colorectal cancer cells. This provides insights for the further 
evaluation of SSNPs in fighting colon cancer. 
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Colorectal cancer (CRC) kills almost 700,000 people annually, 
making it one of the second leading cause of cancer-related deaths 
worldwide and it also accounts for approximately 10% of cancer-
related mortality in Western countries [1-3]. Various factors have 
associated with progression of colon cancer including mutation, 
bacterial infection and irradiation [4-6]. The colon cancer incidence 
is increasing in several countries due to the pervasive adoption of 
the Western diet and lifestyle [7]. For instance, high and frequent 
intake of processed and red meats, preserved foods, 
saturated/animal fats, cholesterol, high sugar and spicy foods, 
tubers, or refined carbohydrates have been positively associated 
with CRC risk [8]. Treatment modalities for primary and metastatic 
CRC are laparoscopic surgery for primary disease, radiotherapy for 
rectal cancer, and neoadjuvant and palliative chemotherapies [9]. 
Targeted therapies with anti-epidermal growth factor receptor have 
also been tried for CRC [10]. Despite significant clinical 
management involving targeted therapies, chemo/radiotherapies, 
and surgical procedures, CRC remains one of the frequent causes 
for cancer-related death worldwide and it is cause for concern [11]. 
Further, chemo/radiotherapy is responsible for off-target side 
effects like nausea, vomiting, diarrhea, mucositis with taste 
alteration, alopecia, constipation, fatigue, anorexia, sleep 
disturbance, headache, anemia and dry skin [12-13]. Therefore, the 
need of the hour is to identify a therapeutic compound for use in 
CRC patients with fewer or no side effects. Nanoparticles based 
phytomedicines are increasingly used as anticancer medicines [14-
15]. Studies showed that various types of metallic and metal oxide 
nanoparticles are employed for the analysis of anticancer potential 
against HT-29 and other gastrointestinal cancer cell lines [16-18]. 
Various metal oxide NPs, including silver oxide, cobalt oxide, 
manganese oxide, titanium dioxide, and zinc oxide, have been 
investigated for their anticancer activities [19-21].  
 
Silibinin is a flavonolignan isolated from the fruit and seeds of the 
medicinal plant Silybum marianum commonly called Milk thistle 
[22] and it is one of the most effective flavonoid compound tested 
against a variety of hepatic disease [22]. Silibinin was also shown to 
have anticancer, antimicrobial, antioxidant, and membrane-
stabilizing properties [13, 22-30]. Silibinin belongs to the group of 
Biopharmaceutics Classification System class II drug and has been 
proven to be very potential drug candidate [31]. However, the 
clinical applications of silibinin show some limitations due to its 
low aqueous solubility and bioavailability, poor penetration into 
the epithelial cells of the intestine, high metabolism, and rapid 
systemic elimination [22,32]. Nonetheless, a nanotechnology-based 
drug delivery system explores the great potential for 
phytochemicals to enhance their aqueous solubility, improve 
stability, and the pharmacological activity [32]. In recent years, 
silver nanoparticles have attracted considerable interest worldwide 
to develop a new-generation treatment tool for cancer because of 
their ability to kill cancer cells [17, 33,34]. Therefore, it is of interest 
to study the cytotoxicity of silibinin assisted silver nanoparticles in 




Dulbecco’s minimum essential low glucose medium (DMEM), 
dimethylsulfoxide (DMSO), penicillin, streptomycin, trypsin-
ethylenediaminetetraacetic acid (EDTA), 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), fetal bovine serum 
(FBS) were obtained from GIBCO BRL (Gaithersburg, MD). 
Silibinin and silver nitrate were purchased from M/s. Sigma 
chemical (Chennai, India). All other chemicals purchased locally 
and were of analytical grade. 
 
Cell culture and maintenance: 
The HT-29 cell line was procured from National Centre for Cell 
Science (Pune, Maharashtra, India). The cells were cultured in 25 
cm2 flask using DMEM with low glucose containing 10% FBS with 
penicillin (100 units/mL) and streptomycin (100 μg/mL) in a 
standard humidified atmosphere with 5% CO2 at 37°C. After 
acclimatization for a couple of passages, cells were used for 
experiments. Once the cells were reached enough confluence, they 
were detached using the trypsin-EDTA solution (0.25%) and were 
seeded for experiments. All the experiments were performed with 
70-80% confluence.  
 
Nanoparticle preparation and characterization: 
Hundred mg of silibinin mixed with 25 mL of double distilled 
water and boiled for 2 min and then 1 mM of silver nitrate (80 mL) 
was added to 20 mL silibinin solution and kept in magnetic stirrer 
for nanoparticles synthesis. The color change was observed visually 
and absorbance was taken from 300-600 nm periodically by UV-
visible spectrophotometry. The synthesized nanoparticles 
centrifuged and dried for the morphology analysis using a 
transmission electron microscope. The sizes of the nanoparticles 
were measured using ImageJ software. The SSNPs were dissolved 
in 0.1% DMSO and used in the following experiments.  
 
MTT assay: 
MTT assay was performed to assess the SSNPs-induced cytotoxicity 
in HT-29 cells [35]. Briefly, cells were seeded at 1 × 104 cells/well in 
96-well plates. 24 h later, the existing medium was changed with 
medium containing different concentrations of SSNPs (2, 4, 6, 8, and 
10 ng/mL) and incubated for 24 h. After 24 h, the media was 
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aspirated and cells were washed with phosphate buffered saline 
(PBS) once and then cells were incubated with 50 μL of MTT (0.5 
mg/mL) for 4 h inside the CO2 incubator. After incubation, MTT 
was discarded and DMSO was added to wells to dissolve the 
colored formazan crystals produced by the viable cells. The purple-
blue formazan formed was measured using Perkin Elmer 
Multimode Reader (USA) at 570 nm. The optical density of each 
sample was compared with control optical density.  
 
Calcein-AM staining assay: 
Cells were treated with 8 and 16 ng/mL of SSNPs and cell viability 
was analyzed by calcein-AM for live cell staining according to the 
manufacturer’s instruction (BD Biosciences, San Jose, CA). Calcein-
AM is a highly lipophilic membrane-permeable vital dye that 
readily enters viable cells and is converted to calcein by esterase 
present in the intracellular domain, which produces an intense 
green fluorescent. Thus, the green color intensity indicates the 
viability of cells. Briefly, after treatments cells were washed twice 
with PBS and were stained with calcein-AM (0.2 μM) and incubated 
for 30 min at 37°C and then images were captured using Nikon 
Eclipse Ti fluorescence microscope (Nikon Instruments Inc., NY, 
USA). 
 
Morphological analysis of apoptosis by annexin V staining: 
HT-29 cells were seeded (1 x 104 cells/well) in 96 well plates and 
after the cell adherence for 24 h; cells were treated with different 
concentrations of SSNPs and incubated for 24 h. At the end of the 
treatment period, cells were collected and fixed in 4% 
paraformaldehyde and subsequently stained with FITC (fluorescein 
isothiocyanate)-annexin V kit (BD Biosciences, San Jose, CA) for 15 
min. Then cells were washed thrice with PBS and representative 
fields were captured immediately using Nikon Eclipse Ti 
fluorescence microscope (Nikon Instruments Inc., NY, USA). 
 
Apoptosis analysis by flow cytometry: 
Briefly, 1 x 106 cells were seeded in 6 well plates and incubated for 
adherence. Then cells were treated with different concentrations of 
SSNPs for 24 h. The apoptotic cells were quantified by annexin V-
FITC/propidium iodide (PI) co-staining assay. Briefly, at the end of 
the 24 h incubation, the cells were harvested and centrifuged at 
1800 rpm for 8 min. The pellet was suspended in 50 μL of binding 
buffer containing 0.5 μL of annexin V-FITC and then incubated at 
4°C for 30 min in the dark. PI (50 μg/mL) in 200 μL binding buffer 
was added and incubated for 5 min. The cells were analyzed in the 
flow cytometer (CyAn ADP Analyzer, Beckman Coulter, USA) [36]. 
Western blot analysis:  
After treatments cells were collected and lysed using RIPA buffer 
containing phosphatase inhibitor cocktails. Total protein estimation 
was done using bovine serum albumin (BSA) as standard. 
Electrophoresis was done with protein extracts and electroblotted 
onto polyvinylidene difluoride membrane. Then the membrane 
was blocked with 5% BSA and incubated overnight with p53 
(monoclonal, IgG1) primary antibody at 4°C and 2 h with the 
corresponding secondary antibodies at room temperature. The 
enhanced chemiluminescence with protein A-horseradish 
peroxidase was used to detect the immunoreactive bands.   
 
Statistical analysis: 
Data were expressed as mean ± S.E.M and analyzed by one-way 
ANOVA followed by Dunnett’s multiple comparison tests to 
determine the significant differences between groups. p<0.05 was 
considered as significant (Graph Pad prism 7.0. CA, USA). 
 
 
Figure 1: Characterization of silibinin assisted silver nanoparticles 
(SSNPs). (A) Visual transmission of SSNPs; (B) UV-Vis spectra of 
biosynthesized SSNPs; (C) Transmission electron microscope 
analysis of SSNPs. 
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Figure 2: Silibinin mediated silver nanoparticles (SSNPs) induced changes in the proliferation of HT-29 cells.  A. Morphology of control 
and SSNPs treated HT-29 cells (scale bar: 100 μm). B. Cytotoxicity analysis by MTT assay. n=3, ***p< 0.001 vs control.    
 
 
Figure 3: Representative fluorescence microscope images (scale bar: 100 μm) show cell viability assessed by calcein AM staining in control 
and silibinin mediated silver nanoparticles (SSNPs) treated HT-29 cells. 
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Figure 4:  (A) Morphological analysis of apoptosis by annexin v staining (4X) (scale bar: 100 μm).  (B). Quantification of apoptotic cells. 
***p<0.001 vs control. 
 
Results: 
In this study, we have used silibinin as a reducing agent to 
synthesize SSNPs. The visual color changes to brown color 
confirmed the syntheses of SSNPs (Figure 1A). The optical 
properties of spherical SSNPs are highly dependent on the 
nanoparticle diameter. In this study, the bioreduction of the silver 
ions was monitored spectro-photometrically at 420 nm. Our UV-
visible spectra showed smaller, spherical SSNPs, which primarily 
absorbed light and had peaks near 420 nm (Figure 1B). The 
transmission electron microscope analysis confirmed that the 
synthesized nanoparticles are mostly spherical and their sizes were 
ranges from 10 to 80 nm (Figure 1C). The morphology of SSNPs 
treated HT-29 cells are presented in Figure 2A. HT-29 cells are 
observed with typical clusters of colonies. Treatment with 
increasing concentrations (2, 4, 6, 8 and 10 ng/mL) of SSNPs 
significantly (p<0.001) inhibited the proliferation of HT-29 cells in a 
dose-dependent manner (Figure 2B). The IC50 value of SSNPs for 
HT-29 cells was found to be 8 ng/mL. Therefore, further studies 
were carried out with the concentration ranges of 8 and 16 ng/mL.  
 
Furthermore, the cytotoxic effect of SSNPs on HT-29 cells was 
confirmed by calcein-AM staining. HT-29 cells were treated with 
two different concentrations (8 and 16 ng/mL) of SSNPs for 24 h 
and live and dead cells were labeled using fluorescent probes 
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calcein AM and photographs were taken under the fluorescence 
microscope. The results demonstrated that the SSNPs are 
decreasing green fluorescence in a dose-dependent manner, which 
indicates decreased viability of HT-29 cells (Figure 3). Annexin v 
staining is one of the gold standard methods to analyze the 
apoptotic changes morphologically. SSNPs treatments in HT-29 
cells caused a dose-dependent increase in annexin v positive cells 
(Figure 4A). The percentage of annexin v positive cells was 
increased in a concentration-dependent manner as compared to 
control cells (p< 0.001) (Figure 4B). The apoptosis-inducing 
potential of SSNPs also analyzed through flow cytometry by 
annexin v and propidium iodide staining. The unstained (without 
annexin v and PI) control cells (with annexin v and PI without 
SSNPs treatments) did not show any significant change in their 
viability and they were 98.5% and 82.1% viable respectively. SSNPs 
treated cells at 8 and 16 ng/ml showed a prominent apoptotic 
change i.e., 70.3% and 83.6% respectively, and decreased viability to 
20% and 11.2% respectively (Figure 5). The tumor suppressor 
protein p53 expression was analyzed in cells treated with SSNPs. 
SSNPs treatments only in high dose caused a significant increase in 
the p53 protein expression when compared to control cells (Figure 
6A). The quantification of p53 expression also confirmed the 
significant increase (16 ng/mL vs p<0.001) upon SSNPs treatments 
(Figure 6B).  
 
 
Figure 5: Flow cytometric analysis of apoptosis using annexin v and propidium iodide staining. Top left quartile percentage indicates the 
presence of apoptotic cells. 
	    
	  
	  
ISSN 0973-2063 (online) 0973-8894 (print)	  
Bioinformation 16(11): 817-827 (2020) 
	  





Figure 6:  (A) Western blot expression of p53. (B). Quantification of p53 protein expression by densitometry analysis. n=3. ***p<0.001 vs 
control.   
 
Discussion: 
Silver nanoparticles range from 1 and 100 nm in size has unique 
properties, which help in molecular diagnostics and therapies [33]. 
Silver nanoparticles are mainly synthesized by the physical and 
chemical methods. The main drawback of the chemical and 
physical methods of silver nanoparticle formation is that they are 
extremely costly and also involve the use of toxic, hazardous 
chemicals and they contain potential environmental and biological 
risks [33,37]. To overcome this, the biological method provides a 
feasible alternative [38]. In our recent study, we have showed β-
Sitosterol, a phytocompound can be used as a good reducing agent 
for synthesis of silver nanoparticles [17]. Phytomediated silver 
nanoparticles were synthesized using Silybum marianum seed 
extract [39]. In this study, we have synthesized spherical silver 
nanoparticles using a phytocompound compound silibinin, and 
tested their cytotoxic potential in HT-29 cells. In previous studies, 
silibinin was shown to have apoptosis and cell cycle arrest potential 
in HT-29 cells [40,41]. Similarly, silver nanoparticles synthesized 
from biological and chemical methods have also shown to have 
apoptosis-inducing potential in HT-29 cells [42,43]. In this study, 
silibinin-mediated silver nanoparticles induced dose-dependent 
cytotoxicity in HT-29 cells. In previous studies, silibinin treatments 
caused cytotoxicity at 50–100 μg/ml [40,41] and however, in this 
study, as compared to silibinin, SSNPs showed prominent cytotoxic 
effect at nanogram levels (8-16 ng/ml) in HT-29 cells. The results of 
the current study suggest that SSNPs are effective against colon 
cancer cells even at nanogram levels. Cell viability can be measured 
using the fluorescent probe calcein-AM, which can differentiate 
between living and dead cells [44]. In viable HT-29 cells, 
intracellular esterase can convert calcein-AM to calcein, which stays 
in living cells and emits intense green fluorescence [45]. In view of 
these reports, the current result suggests that decreased green 
fluorescence intensity in SSNPs treated HT-29 cells is due to fall in 
cell viability, which further supports the toxicity induced by SSNPs. 
 
Apoptosis is one of the commonly reported mechanisms for silver 
nanoparticles induced cytotoxicity in human breast, lung, liver, 
skin and oral cancer cell lines [46-50].  Membrane damage is often 
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reported when the cancer cells are treated with silver nanoparticles 
[49,51] and therefore, morphological changes related to apoptosis 
were investigated by annexin v staining. In the early apoptotic 
stage, phosphatidylserine residues expose from the inner to the 
outer leaflet of the plasma membrane and annexin V precisely bind 
to the exposed phosphatidylserine residues and therefore, it was 
used as a specific probe for morphological investigation of 
apoptosis [35,52]. In our present result presence of green color 
fluorescence in the experimental group indicating the membrane 
damaged cells undergoing apoptosis. The flow cytometry analysis 
also confirms the reduction of viability after SSNPs treatments, 
which further support the apoptosis-inducing potentials of SSNPs 
in HT-29 cells. 
 
Apoptosis is the most noticeable biological outcome of p53 
activation in cell culture experiments as suggested by Chen (2016) 
[53]. p53 is a transcription factor and it can be activated by several 
stress signals including DNA damage, apoptosis, nutrient 
deprivation, and cell-cycle arrest [13, 27, 54]. p53 has the ability to 
induce apoptosis by transcription-dependent and -independent 
manner [55]. Transcriptionally p53 activates the pro-apoptotic Bcl-2 
family proteins and suppresses the anti-apoptotic Bcl-2 family 
proteins. p53 directly interacts with Bax that successively stimulates 
the release of cytochrome C via mitochondrial outer membrane 
permeabilization and aid in the induction of apoptosis through 
caspase activation [53,56,57]. It is likely that the apoptosis inducing 
potentials of SSNPs observed in this study could be due to the 
transcriptional activation of p53 protein expression in HT-29 cells. 
 
Conclusions: 
Silibinin assisted silver nano-particles had a spherical shape with 
an average size of 10 to 80 nm. SSNPs treatments induced dose-
dependent cytotoxicity with a concomitant decrease in the cell 
viability in human colorectal cancer cell line. SSNPs treatment 
induced p53 protein expression and this could be the possible 
reason behind the apoptotic changes observed in this study. Thus, 
SSNPs is a potential therapeutic candidate for in vivo evaluation in 
the fight against colon cancer. 
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